Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 18:58:100595.
doi: 10.1016/j.ahjo.2025.100595. eCollection 2025 Oct.

Evaluating tissue plasminogen activator (tPA) in dialysis catheter dysfunction: A focus on fibrin sheath and risk factors

Javad Jalili  1 , Sarah Vaseghi  1   2 , Touraj Asvadi  2 , Mahdiyeh Baastani Khajeh  1
Affiliations

Evaluating tissue plasminogen activator (tPA) in dialysis catheter dysfunction: A focus on fibrin sheath and risk factors

Javad Jalili et al. Am Heart J Plus. .

Abstract

Background: Hemodialysis catheter dysfunction can arise from fibrin sheath formation, leading to impaired patency and compromised treatment. Tissue plasminogen activator (tPA) is an emerging treatment option to restore catheter patency. This study evaluated the efficacy of tPA therapy and explored clinical and demographic risk factors for catheter dysfunction.

Methods: This retrospective study included 42 hemodialysis patients with central venous catheters (CVCs) at Imam Reza Hospital, Tabriz, Iran (2020-2023). Inclusion criteria were inability to withdraw blood or inadequate flow in one or both catheter lumens, confirmed by venographic evidence of fibrin sheath formation. Patients received 2 mg tPA in 2 ml saline with a 30-min dwell time. Data on patient demographics, catheter history, and tPA outcomes were analyzed.

Results: tPA was effective in 78.6 % of patients after the first dose, restoring both lumens' functionality. Four of the treated cases required a second tPA session due to recurrent fibrin sheath formation within 6-18 months, all of which were successful. Two patients received a third tPA dose 14-16 months after the second, also with complete resolution. Older age (p = 0.02), diabetes (p = 0.001), and smoking (P = 0.015) were identified as significant risk factors for catheter dysfunction.

Conclusion: tPA therapy effectively restores catheter function in cases of fibrin sheath-related dysfunction. Addressing modifiable risk factors such as smoking and managing diabetes may help reduce the incidence of catheter dysfunction and improve long-term outcomes in dialysis patients.

Keywords: Dialysis catheter dysfunction; Fibrin sheath; Thrombolytic therapy; Tissue plasminogen activator (tPA).

PubMed Disclaimer

Conflict of interest statement

I have nothing to declare.

Figures

Fig. 1
Fig. 1
Venography demonstrating fibrin sheath formation around the distal portion of the right internal jugular vein (RIJV) catheter without evidence of thrombosis.
See this image and copyright information in PMC

References

    1. Kietsiriroje N., Ajjan R.A., Grant P.J. In: Cardiovascular Endocrinology and Metabolism. Krentz A.J., Chilton R.J., editors. Academic Press; 2023. Chapter 8 - hemostatic abnormalities associated with diabetes and their clinical implications; pp. 199–220.
    1. Ndumele C.E., Neeland I.J., Tuttle K.R., Chow S.L., Mathew R.O., Khan S.S., et al. A synopsis of the evidence for the science and clinical Management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636–1664. - PubMed
    1. Sohail M.A., Vachharajani T.J., Anvari E. Central venous catheters for hemodialysis—the myth and the evidence. Kidney Int. Rep. 2021;6(12):2958–2968. - PMC - PubMed
    1. Bellinghieri G., Ricciardi B., Costantino G., Torre F., Santoro D., Cimadoro D., et al. Exhaustion of vascular endowment in hemodialysis: proposal for a permanent inlet access. Int. J. Artif. Organs. 1998;21(4):201–204. - PubMed
    1. Carr M.E. Diabetes mellitus: a hypercoagulable state. J. Diabetes Complications. 2001;15(1):44–54. - PubMed

LinkOut - more resources